Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.
Dates: 2010-2013
Funding: Health Technology Assessment Programme
Collaborators: Dept of Psychological Medicine, Imperial College Hospital
Information: Judit Simon

The main aim of the study is to establish the clinical and cost-effectiveness of the SSRI antidepressant, citalopram, in the management of negative symptoms of schizophrenia. The research hypothesis to be tested is that augmentation of stable antipsychotic medication with citalopram, is clinically and cost-effective for ameliorating persistent negative symptoms in schizophrenia and is not associated with an additional side effect burden.